AfterRaise/Companies/Aptadir Therapeutics

Aptadir Therapeutics

Aptadir Therapeutics is a biotech company developing a novel class of RNA inhibitor-based therapeutics for treating intractable genetic conditions. From its funding announcement.

€40M SeedRaised yesterdayMilan, ItalyBiotech & PharmaItaly
Visit website →

In their own words

What Aptadir Therapeutics says it is doing

Work here? Claim your company profile

Public signal Described in the funding announcement as "biotech company developing a novel class of RNA inhibitor-based therapeutics for treating intractable genetic conditions". Source

Research and development

Public signal Read from the company's own description of what the funding supports.

Why now

Where Aptadir Therapeutics is today

Aptadir Therapeutics announced a funding round of €40M on 29 September 2026, led by 4BIO Capital.

Latest round
Seed
Amount
€40M
Announced
29 September 2026
Headquarters
Milan, Italy
Sector
Biotech & Pharma
Investors
Also participating
original pre-seed investor, EXTEND, Italy's National Technology Transfer Hub, launched by CDP Venture Capital SGR, jointly funded by Angelini Ventures, Evotec SE
Relevant leadership
Not stated

Momentum AfterRaise intelligence

AfterRaise Score

66
Building momentum
1 funding signal in the last 90 days
Funding recency
40/40
announced within the last 30 days
Round scale
16/25
round size relative to the market
Funding stage
10/20
Seed
Funding cadence
0/15
one funding event tracked this year
Arriving with the signals layer
  • Hiring momentum Open roles and hiring pace
  • Market expansion New offices and new countries
  • Leadership Executive appointments
  • Product activity Launches and releases

Since the raise

What has happened since

  • 29 September 2026
    €40M Seed
    Led by 4BIO Capital.

Public signal The timeline currently holds funding events, because those are the signals AfterRaise observes today. Hiring, leadership, expansion and product events join it with the signals layer.

What may happen next

What this raise could create

AfterRaise intelligenceNot a statement of fact

What may happen next

  • Research programme expansion
  • Scientific team growth
  • Accelerated hiring across functions
  • Founding team growth

Opportunities this could create

  • Clinical operations
  • Scientific hiring
  • Scientific advisers
  • Research operations
  • Specialist suppliers

Based on the Biotech & Pharma sector, a Seed round and the priorities the company itself set out. Not a statement of fact.

Medium momentum2 connected signals
  • 29 September 2026€40M Seed announced
  • 29 September 2026Stated priority: research and development

High momentum means several meaningful company changes have occurred in a short period. Signals here are funding events and the priorities the company stated; hiring, leadership and expansion detection join with the signals layer.

Open to

What Aptadir Therapeutics is open to

Not yet specified

Aptadir Therapeutics has not told AfterRaise which approaches it welcomes. Until it does, we do not assume. Offers to help are held and shown to the company, and the company decides whether to open a conversation.

Work here? Set your preferences

Opportunities

Ways to work with Aptadir Therapeutics

No open opportunities listed

Jobs, projects, partnerships, advisory and supplier needs appear here once the company has claimed its page and published them, and any role we read from its own job board appears automatically.

Work here? Open the first one

Helpful contributors

People who have contributed here

Nobody yet

When someone offers help and the company says it was useful, they appear here. Reputation on AfterRaise is built from contributions the company confirmed, not from follower counts.

Do you work at Aptadir Therapeutics?

Claim your company profile.

This page was created from publicly available information. A verified representative corrects the record, says what the company is building next and chooses which conversations it welcomes.

What we do not have yet: the roles and projects you have open and who leads the team. Claiming the page is how you fill those in.

Someone else requesting access does not give them ownership. Every representative is verified by a person before access is granted.

Maintaining your own company profile is free. A founder, CEO or authorised senior colleague can represent the company.

Also moving

Other Biotech & Pharma companies

See the sector